Arsenic trioxide and acute promyelocytic leukemia: Clinical and biological

Current Topics in Microbiology and Immunology

Volumn 313, Issue , 2007, Pages 129-144

  Chen, Z ^a   Zhao, W L ^a   Shen, Z X ^a   Li, J M ^a   Chen, S J ^a   Zhu, J ^a,b   Lallemand Breittenbach, V ^b   Zhou, J ^a,b   Guillemin, M C ^b   Vitoux, D ^b   De The H ^b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; HYDROXYUREA; IDARUBICIN; MERCAPTOPURINE; METHOTREXATE; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; ORGANOARSENIC DERIVATIVE; OXIDE;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SURVIVAL; CARDIOTOXICITY; CONTINUOUS INFUSION; COUGHING; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HAIR LEVEL; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; DRUG WITHDRAWAL; EPISTAXIS; FACE EDEMA; FATIGUE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; GINGIVA BLEEDING; HUMAN; HYPERGLYCEMIA; HYPOKALEMIA; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTOSIS; LIVER TOXICITY; LOW DRUG DOSE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR DYNAMICS; MOUTH ULCER; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NONHUMAN; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RETINOIC ACID SYNDROME; REVIEW; SALIVARY GLAND; SIDE EFFECT; SKIN TOXICITY; THYROID GLAND; TOOTH PAIN; XEROSTOMIA; CLINICAL TRIAL; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ARSENICALS; CLINICAL TRIALS; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; OXIDES; TREATMENT OUTCOME;

EID: 33846992732     PISSN: 0070217X     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-34594-7_8     Document Type: Review

References (53)

1. 3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood 88:1052-1061
2. Chen GQ, Shen ZX, Wu F, Han JY, Miao JM, Zhong HJ, Li XS, Zhao JQ, Zhu J, et al (1996b) Pharmacokinetics and efficacy of low-dose all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Leukemia 10:825-828
3. Chen Z, Wang ZY, Chen SJ (1997) Acute promyelocytic leukemia: cellular and molecular basis of differentiation and apoptosis. Pharmacol Ther 76:141-149
4. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A (1990) The t(15;17) translocation of acute promyelocytic leukemia fuses the retinoic acid receptor a gene to a novel transcribed locus. Nature 347:558-561
5. de Thé H, Lavau C, Marchio A, Chomienne C, Degos L, Dejean A (1991) The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 66:675-684
6. Di Croce L, Raker VA, Corsaro M, Fazi F, Fanelli M, Faretta M, Fuks F, Coco FL, Kouzarides T, Nervi C, Minucci S, Pelicci PG (2002) Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science 295:1079-1082
7. Duprez E, Saurin AJ, Desterro JM, Lallemand-Breitenbach V, Howe K, Boddy MN, Solomon E, de Thé H, Hay RT, Freemont PS (1999) SUMO-1 modification of the acutepromyelocytic leukaemia protein PML:implications fornuclear localisation. J Cell Sci 112:381-393
8. Grignani F, de Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391:815-818
9. Hayakawa F, Privalsky ML (2004) Phosphorylation of PML by mitogen-activated protein kinases plays a key role in arsenic trioxide-mediated apoptosis. Cancer Cell 5:389-401
10. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A, Pandolfi PP (1998) Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet 18:126-135
11. Jansen JH, Mahfoudi A, Rambaud S, Lavau C, Wahli W, Dejean A (1995) Multimeric complexes of the PML-retinoic acid receptor alpha fusion protein in acute promyelocytic leukemia cells and interference with retinoid and peroxisome-proliferator signaling pathways. Proc Natl Acad Sci USA 92:7401-7405
12. Jing Y, Wang L, Xia L, Chen G, Chen Z, Miller WH, Waxman S (2001) Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo. Blood 97:264-269
13. Kamashev DE, Vitoux D, De Thé H (2004) PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP in APL cell differentiation. J Exp Med 199:1-13
14. Kamitani T, Kito K, Nguyen HP, Wada H, Fukuda-Kamitani T, Yeh ETH (1998a) Identification of three major sentrinization sites in PML. J Biol Chem 41:26675-26682
15. Kamitani T, Nguyen HP, Kito K, Fukuda-Kamitani T, Yeh ET (1998b) Covalent modification of PML by the sentrin family of ubiquitin-like proteins. J Biol Chem 273:3117-3120
16. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de Thé H (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189:1043-1052
17. Lallemand-Breitenbach V, Zhu J, Puvion F, Koken M, Honore N, Doubeikovsky A, Duprez E, Pandolfi PP, Puvion E, Freemont P, de Thé H (2001) Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As(2)O(3)-induced PML or PML/retinoic acid receptor alpha degradation. J Exp Med 193:1361-1372
18. 3) in the treatment of patients with acute promyelocytic leukemia: the MD Anderson experience. Cancer 97:2218-2224
19. Lin R, Evans R (2000) Acquisition of oncogenic potential by RAR chimeras in acute promyelocytic leukemia through formation of homodimers. Mol Cell 5:821-830
20. Lin RJ, Nagy L, Inoue S, Shao WL, Miller WH, Evans RM (1998) Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 391:811-814
21. Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A (2002) Arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: a single center experience. Am J Hematol 70:292-299
22. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S (2002) Mechanisms of action of arsenic trioxide. Cancer Res 62:3893-3903
23. Minucci S, Maccarana M, Cioce M, De Luca P, Gelmetti V, Segalla S, Di Croce L, Giavara S, Matteucci C, Gobbi A, Bianchini A, Colombo E, Schiavoni I, Badaracco G, Hu X, Lazar MA, Landsberger N, Nervi C, Pelicci PG (2000) Oligomerization of RAR and AML1 transcription factors as a novel mechanism of oncogenic activation. Mol Cell 5:811-820
24. Muller S, Matunis MJ, Dejean A (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17:61-70
25. Nervi C, Poindexter EC, Grignani F, Pandolfi PP, Lo Coco F, Avvisati G, Pelicci PG, Jetten AM (1992) Characterization of the PML-RAR alpha chimeric product of the acute promyelocytic leukemia-specific t(15; 17) translocation. Cancer Res 52:3687-3692
26. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C, Diverio D, Grignani F, Pelicci PG, Testi R (1998) Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 92:2244-2251
27. Niu C, Yan H, Yu T, Sun HP, Liu JX, et al (1999) Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94:3315-3324
28. Perez A, Kastner P, Sethi S, Lutz Y, Reibel C, Chambon P (1993) PML/RARhomodimers: distinct binding properties and heteromeric interactions with RXR. EMBO J 12:3171-3182
29. Quignon F, Chen Z, de Thé H (1997) Retinoic acid and arsenic: towards oncogene targeted treatments of acute promyelocytic leukaemia. Biochim Biophys Acta 1333:M53-M61
30. Quignon F, de Bels F, Koken M, Feunteun J, Ameisen JC, de Thé H (1998) PML induces a caspase-independent cell death process. Nat Genet 20:259-265
31. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Rea D, Buzyn A, Tibi A, Lebbe G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H (2003) Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol 21:2326-2334
32. 3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci U S A 97:10173-10178
33. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG, Ballabio A (2001) The tripartite motif family identifies cell compartments. EMBO J 20:2140-2151
34. Salomoni P, Pandolfi PP (2002) The role of PML in tumor suppression. Cell 108:165-170
35. Seeler JS, Dejean A (2001) SUMO: of branched proteins and nuclear bodies. Oncogene 20:7243-7249
36. Shen Y, Shen ZX, Yan H, Chen J, Zeng XY, Li JM, Li XS, Wu W, Xiong SM, Zhao WL, Tang W, Wu F, Liu YF, Niu C, Wang ZY, Chen SJ, Chen Z (2001) Studies on the clinical efficacy and pharmacokinetics of low-dose arsenic trioxide in the treatment of relapsed acute promyelocytic leukemia: a comparison with conventional dosage. Leukemia 15:735-741
37. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Use of arsenic trioxide (As203) in the treatment of acute promyelocytic leukemia (APL). II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360
38. 3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A 101:5328-5335
39. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutre S, Dahlberg S, Ellison R, Warrell RP Jr (2001) United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 19:3852-3860
40. Sun HD, Ma L, Hu HX, Zhang TD (1992) Use of Ai-Ling n. 1 injection, combined with pattern identification theory of Chinese traditional medicine, in the treatment of acute promyelocytic leukemia: report from 32 patients. Zhongguo Zhong Xi Yi Jie He Za Zhi 12:170-171
41. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP (1998a) PML is essential for multiple apoptotic pathways. Nat Genet 20:266-272
42. Wang ZG, Delva L, Gaboli M, Rivi R, Giorgio M, Cordon-Cardo C, Grosveld F, Pandolfi PP (1998b) Role of PML in cell growth and the retinoic acid pathway. Science 279:1547-1551
43. Warrell R, de Thé H, Wang Z, Degos L (1993) Acute promyelocytic leukemia. N Engl J Med 329:177-189
44. Zhang P, Wang SY, Hu XH, et al (1996) Arsenic trioxide-treated 72 cases of acute promyelocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 17:58-60
45. Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, Li X, Han X, Zhou J, Liu P (2000) Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide - an analysis of 242 cases (in Chinese). Zhonghua Xue Ye Xue Za Zhi 21:67-70
46. Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH, Xiao DK, Shen SH, Imbeaud S, Eveno E, Zhao CJ, Chen YL, Fan HY, Waxman S, Auffray C, Jin G, Chen SJ, Chen Z, Zhang J (2005) Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A 102:7653-7658
47. Zhou GB, Zhao WL, Wang ZY, Chen SJ, Chen Z (2005) Retinoic acid and arsenic for treating acute promyelocytic leukemia. PLoS Med 2:12
48. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de Thé H (1997) Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:3978-3983
49. Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, Koken M, Quignon F, Rochette-Egly C, de Thé H (1999) Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RAR alpha) and oncogenic RAR alpha fusion proteins. Proc Natl Acad Sci U S A 96:14807-14812
50. Zhu J, Lallemand-Breitenbach V, de Thé H (2001) Pathways of retinoic acid- or arsenic trioxide-induced PML/RARalpha catabolism, role of oncogene degradation in disease remission. Oncogene 20:7257-7265
51. Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H (2002a) How acute promyelocytic leukemia revived arsenic. Nat Rev Cancer 2:705-713
52. Zhu Q, Zhang JW, Zhu HQ, Shen YL, Flexor M, Jia PM, Yu Y, Cai X, Waxman S, Lanotte M, Chen SJ, Chen Z, Tong JH (2002b) Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 99:1014-1022
53. Zhu J, Zhou J, Peres L, Riaucoux F, Honore N, Kogan S, de Thé H (2005) A sumoylation site in PML/RARAis essential for leukemic transformation. Cancer Cell 7:143-153